Publications:  Mr Wayne Huttly

WALD NJ, LAU KW, BESTWICK J, Old R, HUTTLY W, CHENG R(2018). Specifying a Gold-Standard for the validation of fetal fraction estimation in prenatal screening. Clinical Chemistry vol. 64, (9) 1394-1399.

BESTWICK JP, HUTTLY W, WALD N(2018). Serum marker truncation limits in first trimester antenatal screening for trisomy 18. Journal of Medical Screening

Wald NJ, Huttly WJ, Bestwick JP, Old R, Morris JK, Cheng R, Aquilina J, Peregrine E et al.(2018). Response to Walker. Genet Med

WALD NJ, Huttly WJ, Bestwick JP, Old R, Morris JK, Cheng R, Aquilina J, Peregrine E et al.(2017). Prenatal reflex DNA screening for trisomy 21, 18, and 13. Genetics in Medicine

Bestwick JP, Huttly WJ, Wald NJ(2017). Pregnancy-associated plasma protein-A truncation limits in antenatal screening for trisomy 18. J Med Screen969141316688499-969141316688499.

Huttly WJ, Bestwick JP, Wald NJ(2016). Insulin dependent diabetes mellitus (IDDM) and first trimester markers in prenatal screening for Down syndrome. Prenatal Diagnosis vol. 36, (2) 192-193.

Wald NJ, Huttly WJ, Bestwick JP, Aquilina J, Peregrine E(2015). Reflex antenatal DNA screening for Down syndrome. Prenatal Diagnosis vol. 35, (11) 1154-1154.

Bestwick JP, Huttly WJ, Wald NJ(2015). Untitled. JOURNAL OF MEDICAL SCREENING vol. 22, (1) 52-54.

Bestwick JP, Huttly WJ, Wald NJ(2014). The estimation of median nuchal translucency values between 10 and 14 weeks of pregnancy. J Med Screen vol. 21, (2) 110-112.

Huttly W, Bestwick J, Wald N(2014). Effect of smoking status on inhibin-A in second-trimester prenatal screening for Down syndrome. Prenat Diagn vol. 34, (4) 406-407.

Bestwick JP, Huttly WJ, Morris JK, Wald NJ(2014). Prevention of neural tube defects: a cross-sectional study of the uptake of folic acid supplementation in nearly half a million women. PLoS One vol. 9, (2)

Bestwick JP, Huttly WJ, Wald NJ(2013). Detection of trisomy 18 and trisomy 13 using first and second trimester Down's syndrome screening markers. J Med Screen vol. 20, (2) 57-65.

Bestwick JP, Huttly WJ, Wald NJ(2013). Allowing for ethnic group in antenatal screening for Down's syndrome. J Med Screen vol. 20, (1) 52-54.

Wald NJ, Bestwick JP, Huttly WJ(2013). Improvements in antenatal screening for Down's syndrome. J Med Screen vol. 20, (1) 7-14.

Bestwick JP, Huttly WJ, Wald NJ(2013). Allowing for ethnic group in antenatal screening for Down's syndrome. JOURNAL OF MEDICAL SCREENING vol. 20, (1) 52-54.

Huttly WJ, Wald NJ(2012). The estimation of gestational age of pregnancy for use in screening for Down syndrome using ultrasound measurements and embryo transfer date. Prenat Diagn vol. 32, (10) 1008-1009.

Wald NJ, Bestwick JP, Huttly WJ(2012). Effect of interrupting prenatal Down syndrome screening due to a large nuchal translucency. Prenat Diagn vol. 32, (7) 655-661.

Bestwick JP, Huttly WJ, Wald NJ(2012). Unconjugated estriol values between 14 and 22 weeks of gestation in relation to prenatal screening for Down syndrome. Prenatal Diagnosis vol. 32, (7)

Bestwick JP, Huttly WJ, Wald NJ(2012). Unconjugated estriol values between 14 and 22 weeks of gestation in relation to prenatal screening for Down syndrome. Prenat Diagn vol. 32, (3) 299-301.

Wald NJ, Bestwick JP, George LM, Huttly WJ(2012). Antenatal screening for Down syndrome using serum placental growth factor with the combined, quadruple, serum integrated and integrated tests. PLoS One vol. 7, (10)

Huttly WJ, Wald NJ(2011). An audit of the detection of trisomy 18 in prenatal screening for Down syndrome using the Combined test. Prenat Diagn vol. 31, (13)

Filippi E, Staughton J, Peregrine E, Jones P, Huttly W, Peebles DM, Pandya P, David AL(2011). Uterine artery Doppler and adverse pregnancy outcome in women with extreme levels of fetoplacental proteins used for Down syndrome screening. Ultrasound Obstet Gynecol vol. 37, (5) 520-527.

Filippi E, Staughton J, Peregrine E, Jones P, Huttly W, Peebles D, Pandya P, David A(2010). Uterine artery Doppler and adverse pregnancy outcome in women with extreme levels of feto-placental proteins used for Down's syndrome screening. Ultrasound Obstet Gynecol

Bestwick JP, Huttly WJ, Wald NJ(2010). Distribution of nuchal translucency in antenatal screening for Down's syndrome (vol 17, pg 8, 2010). J MED SCREEN vol. 17, (2) 106-106.

Bestwick JP, Huttly WJ, Wald NJ(2010). Distribution of nuchal translucency in antenatal screening for Down's syndrome. J Med Screen vol. 17, (1) 8-12.

Bestwick JP, Huttly WJ, Wald NJ(2010). Evaluation of a proposed mixture model to specify the distributions of nuchal translucency measurements in antenatal screening for Down's syndrome. J Med Screen vol. 17, (1) 13-18.

Wald NJ, Huttly WJ, Murphy KW, Ali K, Bestwick JP, Rodeck CH(2009). Antenatal screening for Down's syndrome using the Integrated test at two London hospitals. J Med Screen vol. 16, (1) 7-10.

Wald NJ, Huttly WJ, Bestwick JP(2008). Inhibin-A concentrations between 14 and 22 weeks of gestation. Prenat Diagn vol. 28, (4) 360-361.

Bestwick JP, Huttly WJ, Wald NJ(2008). First trimester Down's syndrome screening marker values and cigarette smoking: new data and a meta-analysis on free beta human chorionic gonadotophin, pregnancy-associated plasma protein-A and nuchal translucency. J Med Screen vol. 15, (4) 204-206.

Weisz B, Pandya PP, David AL, Huttly W, Jones P, Rodeck CH(2007). Ultrasound findings after screening for Down syndrome using the integrated test. Obstet Gynecol vol. 109, (5) 1046-1052.

Weisz B, Pandya P, Chitty L, Jones P, Huttly W, Rodeck C(2007). Practical issues drawn from the implementation of the integrated test for Down syndrome screening into routine clinical practice. BJOG vol. 114, (4) 493-497.

Huttly WJ, Morris JK, Bestwick JP, Wald NJ, Murphy K, Pandya PP(2006). Three stage contingent screening for Down syndrome. Prenat Diagn vol. 26, (12)

Wald NJ, Barnes IM, Birger R, Huttly W(2006). Effect on Down syndrome screening performance of adjusting for marker levels in a previous pregnancy (vol 26, pg 539, 2006). PRENATAL DIAGNOSIS vol. 26, (6) 589-589.

Wald NJ, Barnes IM, Birger R, Huttly W(2006). Effect on Down syndrome screening performance of adjusting for marker levels in a previous pregnancy. Prenat Diagn vol. 26, (6) 539-544.

Wald NJ, Bestwick JP, Huttly WJ, Morris JK, George LM(2006). Validation plots in antenatal screening for Down's syndrome. J Med Screen vol. 13, (4) 166-171.

Wald NJ, Huttly WJ, Rudnicka AR(2004). Recurrent false-positives in AFP screening for open neural tube defects. Prenat Diagn vol. 24, (12) 1018-1019.

Huttly W, Rudnicka A, Wald NJ(2004). Second-trimester prenatal screening markers for Down syndrome in women with insulin-dependent diabetes mellitus. Prenat Diagn vol. 24, (10) 804-807.

RUDNICKA AR, Wald NJ, Huttly WJ(2004). Parental screening for Downs syndrome: the problem of recurrent false-positives. Prenatal Diagnosis. vol. 24, 389-392.

Rudnicka AR, WALD NJ, Huttly W(2004). Prenatal screening for Down syndrome: the problem of recurrent false-positives. Prenatal Diagnosis. vol. 24, (5) 389-392.

Alberman E, Huttly W, Hennessy E, McIntosh A(2003). The use of record linkage for auditing the uptake and outcome of prenatal serum screening and prenatal diagnostic tests for Down syndrome. Prenat Diagn vol. 23, (10) 801-806.

Wald NJ, Huttly WJ, Hackshaw AK(2003). Antenatal screening for Down's syndrome with the quadruple test. Lancet vol. 361, (9360) 835-836.

Wald NJ, Huttly W, Hackshaw AK, Christiansen M, Larsen SO, Nørgaard-Pedersen B, Howe D, Wellesley D(2002). Antenatal screening policies for Down's syndrome [3] (multiple letters). British Medical Journal vol. 325, (7371) 1034-1035.

Wald NJ, Huttly W, Hackshaw AK(2002). Antenatal screening policies for Down's syndrome. Audit of Down's syndrome screening is not valid. BMJ vol. 325, (7371)

Rudnicka AR, Wald NJ, Huttly W, Hackshaw AK(2002). Influence of maternal smoking on the birth prevalence of Down syndrome and on second trimester screening performance. Prenat Diagn vol. 22, (10) 893-897.